Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
We are constantly supporting #innovation. That is why we started off #UCBVentures, a corporate venture fund established in 2017. We invest in early stage and higher risk opportunities, in areas adjacent & beyond UCB’s therapeutic focus #UCB90 #Innovation https://t.co/rbRFqlkH21 https://t.co/s8ftjEijmK
— UCB News (@ucb_news) 13.08.2018 -
A calcium & vitamin D rich diet, exercise and not smoking can help you develop healthy bones and prevent osteoporosis later in life. Find out how #Osteoporosis affects people in our latest #OsteoporosisInsights https://t.co/zCnBLJonvA https://t.co/MBwhdol1Qm
— UCB News (@ucb_news) 13.08.2018 -
We are one of the founding members of the EU@IMI_JU, a collaborative and innovative approach to some of the biggest challenges in medical research and drug development today #UCB90 #DrivenByScience #Partnership https://t.co/oSt7lLzptU
— UCB News (@ucb_news) 10.08.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
